Lenz Therapeutics, INC

Lenz Therapeutics reports a director's resignation and a subsequent adjustment to the Board size and Audit Committee composition.

LENZ Therapeutics shareholders re-elected Class II directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

LENZ Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting a successful initial launch of VIZZ for presbyopia with $1.6 million in net product revenue.

LENZ Therapeutics announced preliminary unaudited Q4 2025 financial results, reporting $1.6 million in VIZZ net product revenue and over 20,000 prescriptions filled.

LENZ Therapeutics, Inc. reported an adverse event of a retinal tear in a patient using VIZZ, noting pre-existing risk factors and an uncertain causal link.

LENZ Therapeutics announced its third quarter 2025 financial results, highlighting the successful commercial launch of VIZZ for presbyopia and a strong cash position.

LENZ Therapeutics, Inc. announced its third-quarter 2025 financial results, highlighting the FDA approval and commercial launch of VIZZ for presbyopia, alongside increased operating expenses for market expansion.

LENZ Therapeutics reported robust Phase 3 CLARITY data for its lead presbyopia treatment, LNZ100, as it progresses towards a potential Q4 2025 commercial launch following an August 2025 FDA decision and expands global licensing agreements.

Lenz Therapeutics announces its Q1 2025 financial results, focusing on the progress of its lead product candidate, LNZ100, towards potential FDA approval and commercial launch.

Lenz Therapeutics reports a net loss of $10.2 million for the third quarter of 2024, alongside updates on their lead product candidate, LNZ100.

Lenz Therapeutics reports its second quarter 2024 results, highlighting the completion of a reverse merger, a private placement, and the submission of an NDA for LNZ100.

Lenz Therapeutics reports its first quarter 2024 financial results, highlighting the completion of a reverse merger and a focus on the upcoming launch of their lead product candidate, LNZ100.

LENZ Therapeutics commercially launched VIZZ, its FDA-approved presbyopia eye drop, in the U.S. in August 2025, generating initial product sales while continuing to incur significant net losses.

Lenz Therapeutics files its 10-K, outlining its focus on developing and commercializing LNZ100, a novel eye drop for presbyopia, with a PDUFA target action date set for August 8, 2025.

Graphite Bio discontinues its gene editing programs, restructures operations, and enters into a merger agreement with LENZ Therapeutics, marking a significant strategic shift.

RA Capital Management reports a stock option grant for Dr. Zachary Scheiner, a director at LENZ Therapeutics, Inc.

Director Jeffrey P. George was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of standard compensation.

Director Kimberlee C. Drapkin was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of standard compensation.

Director James W. McCollum was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's director compensation policy.

Director Shelley B. Thunen was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's compensation policy.

Director Frederic Guerard was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's director compensation policy.

LENZ Therapeutics will hold its annual stockholders meeting on June 10, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the independent auditor.

LENZ Therapeutics announces its annual meeting of stockholders to be held virtually on June 10, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Lenz Therapeutics registers the resale of 1,578,947 shares of common stock issued in a July 2024 private placement, following its merger with Graphite Bio.

LENZ Therapeutics files an amendment to its S-1 registration statement, covering the resale of 1,297,411 shares of common stock issued in a PIPE financing following its recent merger with Graphite Bio.

Lenz Therapeutics registers for the resale of 1,297,411 shares of common stock issued in a PIPE financing following its merger with Graphite Bio.

Versant Venture Capital funds have reported a material decrease in their aggregate beneficial ownership of LENZ Therapeutics, Inc. common stock, driven by share sales and dilution.

RA Capital Management and its affiliates report a dilution of their beneficial ownership in LENZ THERAPEUTICS, INC. to 13.6% of common stock outstanding.

Versant Venture Capital entities have significantly reduced their beneficial ownership in LENZ Therapeutics, Inc. through a series of stock sales in August and September 2025.

Versant Venture Capital funds have reduced their beneficial ownership in LENZ Therapeutics, Inc. through recent share sales totaling over $10 million.

Versant Venture Capital VI, L.P. has significantly reduced its beneficial ownership in LENZ Therapeutics, Inc. through two recent stock sales totaling over $12.5 million.

Versant Venture Capital VI, L.P. and Versant Venture Capital VII, L.P. have reported significant sales of LENZ Therapeutics, Inc. common stock, reducing their beneficial ownership.

Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in LENZ Therapeutics, Inc.

Multiple Squarepoint entities have collectively reported beneficial ownership of over 5% of LENZ Therapeutics, Inc. common stock.

FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 11.8% of LENZ THERAPEUTICS INC common stock as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.9% of LENZ THERAPEUTICS, INC.'s common stock as of December 31, 2025.

Paradigm BioCapital Advisors LP and its affiliates have reduced their beneficial ownership in LENZ Therapeutics, Inc. to below the 5% threshold, as disclosed in an amended Schedule 13G filing.

Steven A. Cohen's Point72-affiliated entities have disclosed a 4.8% beneficial ownership stake in LENZ Therapeutics, Inc. as of September 30, 2025.